Review: Thyroid cancer: Emerging role for targeted therapies

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 1, 2010, Pages 3-16

  Sipos, Jennifer A ^a   Shah, Manisha H ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

targeted therapy; thyroid cancer; tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CAPECITABINE; CELECOXIB; COMBRETASTATIN A4 PHOSPHATE; CYCLOOXYGENASE 2 INHIBITOR; DACARBAZINE; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MOTESANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; ROSIGLITAZONE; SORAFENIB; VANDETANIB; VORINOSTAT; XL 184;

ADENOMATOUS POLYP; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; ARTHRALGIA; CHOLECYSTITIS; CLINICAL TRIAL; COLON POLYP; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FATIGUE; HAND FOOT PAIN; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INFECTION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG EMBOLISM; LYMPHOCYTOPENIA; METASTASIS; NAUSEA; ONCOCYTOMA; PAIN; PALMOPLANTAR ERYTHEMA; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN DEFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROTROPIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 77953368220     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009352667     Document Type: Review

References (62)

1. Aiello, A., Pandini, G., Frasca, F., Conte, E., Murabito, A., Sacco, A. et al. (2006) Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147: 4463-4475.
2. Akslen, L.A. and Livolsi, V.A. ( 2000) Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol 31: 439-442.
3. Argiris, A., Agarwala, S.S., Karamouzis, M.V., Burmeister, L.A. and Carty, S.E. ( 2008) A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 26: 183-188.
4. Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A. et al. (2002) The kinase inhibitor PP 1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62: 1077-1082.
5. Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S.M. et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334.
6. Chen, K.T., Lin, J.D., Liou, M.J., Weng, H.F., Chang, C.A. and Chan, E.C. ( 2006) An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines. Cancer Lett 231: 192-205.
7. Chow, S.M., Law, S.C., Mendenhall, W.M., Au, S.K., Chan, P.T., Leung, T.W. et al. (2002) Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 52: 784-795.
8. Cohen, E.E., Rosen, L.S., Vokes, E.E., Kies, M.S., Forastiere, A.A., Worden, F.P. et al. (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26: 4708-4713.
9. Cooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J. et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109-141.
10. Davies, L. and Welch, H.G. ( 2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
11. de Groot, J.W., Plaza, M., Schepers, I., Drenth-Diephuis, H., Osinga, L.J., Plukker, J.J.T. et al. (2006) Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia type 2A and 2B associated RET mutations. Surgery 139: 806-814.
12. de Groot, J.W., Zonnenberg, B.A., Quarles, U.-M., de Vries, M.M., Links, T.P., Lips, C.J. et al. (2007) A phase-II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92: 3466-3469.
13. Dowlati, A., Robertson, K., Cooney, M., Petros, W.P., Stratford, M., Jesberger, J. et al. (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416.
14. Droz, J.P., Schlumberger, M., Rougier, P., Ghosn, M., Gardet, P. and Parmentier, C. ( 1990) Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76: 480-483.
15. Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E. et al. (2007) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10 years follow up study. J Clin Endocrinol Metab 93: 682-687.
16. Enewold, L., Zhu, K., Ron, E., Marrogi, A.J., Stojadinovic, A., Peoples, G.E. et al. (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18: 784-791.
17. Eng, C., Clayton, D., Schufenecker, I., Lenoir, G., Cote, G., Gagel, R.F. et al. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276: 1575-1579.
18. Fury, M.G., Solit, D.B., Su, Y.B., Rosen, N., Sirotnak, F.M., Smith, R.P. et al. (2007) A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 59: 467-475.
19. Gimm, O., Neuberg, D.S., Marsh, D.J., Dahia, P.L.M., Cuong, H.V., Raue, F. et al. (1999) Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 18: 1369-1373.
20. Gorgoulis, V., Aninos, D., Priftis, C., Evagelopoulou, C., Karameris, A., Kanavaros, P. et al. (1992) Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors. In Vivo 6: 291-296.
21. Gupta-Abramson, V., Troxel, A.B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K. et al. (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26: 4714-4719.
22. Ha, H.T., Lee, J.S., Urba, S., Koenig, R.J., Sisson, J., Giordano, T. et al. (2009) Phase II trial evaluating imatinib (I) in patients (pts) with anaplastic thyroid carcinoma (ATC). J Clin Oncol 27: Abstract 6057.
23. Hayat, M.J., Howlader, N., Reichman, M.E. and Edwards, B.K. ( 2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12: 20-37.
24. Hoffmann, S., Glaser, S., Wunderlich, A., Lingelbach, S., Dietrich, C., Burchert, A. et al. (2006 a) Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors-a novel antiproliferative / antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 391: 589-596.
25. Hoffmann, S., Wunderlich, A., Celik, I., Maschuw, K., Hassan, I., Hofbauer, L.C. et al. (2006 b) Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. J Cell Biochem 98: 954-965.
26. Jhiang, S.M., Sagartz, J.E., Tong, Q., Parker-Thornburg, J., Capen, C.C., Cho, J.Y. et al. (1996) Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137: 375-378.
27. Kamba, T., Tam, B.Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M.R. et al. (2006) VEGFdependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576.
28. Kebebew, E., Greenspan, F.S., Clark, O.H., Woeber, K.A. and McMillan, A. ( 2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103: 1330-1335.
29. Kebebew, E., Lindsay, S., Clark, O., Woeber, K.A., Hawkins, R. et al. (2009) Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19: 953-956.
30. Kelly, W.K., O'Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T. et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923-3931.
31. Kim, S., Yazici, Y.D., Calzada, G., Wang, Z.Y., Younes, M.N., Jasser, S.A. et al. (2007) Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6: 1785-1792.
32. Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E. and Fagin, J.A. ( 2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
33. Klein, M., Picard, E., Vignaud, J.M., Marie, B., Bresler, L., Toussaint, B. et al. (1999) Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161: 41-49.
34. Kloos, R.T., Ringel, M.D., Knopp, M.V., Hall, N.C., King, M., Stevens, R. et al. (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27: 1675-1684.
35. Kolaric, K., Maricic, Z., Nola, P. and Krusic, J. ( 1977) Modified administration schedule of adriamycin in solid tumors. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 88: 255-260.
36. Kondo, T., Ezzat, S. and Asa, S.L. ( 2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306.
37. Kurzrock, R., Sherman. S., Hong, D., Ng, C., Frye, J., Janisch, L. et al. (2008) A phase 1 study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC). The AACR-NCI-EORTC International Conference, Molecular Targetsand Cancer Therapeutics, Discovery, Biology, and Clinical Applications October 21-24, 2008, Geneva, Switzerland.
38. Lam, E.T., Ringel, M.D., Kloos, R.T., Collamore, M., Arbogast, D., Liang, J. et al. (2009) A phase II study of sorafenib in patients with metastatic medullary thyroid carcinoma. 100th AACR Annual meeting, Abstract 4513, April 18-22, San Diego, CA.
39. Lo, C.Y., Lam, K.Y., Leung, P.P. and Luk, J.M. ( 2005) High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. Eur J Endocrinol 152: 545-550.
40. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
41. Mitsiades, C.S., Sykoutri, D., McMullan, C., Poulaki, V. and Mitsiades, N. ( 2003) Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 88: 5043-5044.
42. Mitsiades, C.S., Poulaki, V., McMullan, C., Negri, J., Fanourakis, G., Goudopoulou, A. et al. (2005) Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 11: 3958-3965.
43. Mooney, C.J., Nagaiah, G., Fu, P., Wasman, J.K., Cooney, M.M., Savvides, P.S. et al. (2009) A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19: 233-240.
44. Mrozek, E., Kloos, R.T., Ringel, M.D., Kresty, L., Snider, P., Arbogast, D. et al. (2006) Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91: 2201-2204.
45. Nagaiah, G., Fu, P., Wasman, J.K., Cooney, M.M., Mooney, C., Afshin, D. et al. (2009) Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 27: Abstract 6058.
46. Neff, R.L., Farrar, W.B., Kloos, R.T. and Burman, K.D. ( 2008) Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37: 525-538, xi.
47. Pennell, N.A., Daniels, G.H., Haddad, R.I., Ross, D.S., Evans, T., Wirth, L.J. et al. (2008) A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18: 317-323.
48. Podtcheko, A., Ohtsuru, A., Tsuda, S., Namba, H., Saenko, V., Nakashima, M. et al. (2003) The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88: 1889-1896.
49. Rosen, L.S., Kurzrock, R., Mulay, M., van Vugt, A., Purdom, M., Ng, C. et al. (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 2369-2376.
50. Rugo, H.S., Herbst, R.S., Liu, G., Park, J.W., Kies, M.S., Steinfeldt, H.M. et al. (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23: 5474-5483.
51. Scherubl, H., Raue, F. and Ziegler, R. ( 1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116: 21-23.
52. Schlumberger, M.J., Elisei, R., Bastholt, L., Wirth, L.J., Martins, R.G., Locati, L.D. et al. (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27: 3794-3801.
53. Sherman, I.S., Wirth, L.J., Droz, J.P., Hofmann, M., Bastholt, L., Martins, R.G. et al. (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359: 31-42.
54. Soh, E.Y., Eigelberger, M.S., Kim, K.J., Wong, M.G., Young, D.M., Clark, O.H. et al. (2000) Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 128: 1059-1065.
55. Specht, M.C., Tucker, O.N., Hocever, M., Gonzalez, D., Teng, L. and Fahey III, T.J. ( 2002) Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 87: 358-363.
56. Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon, G.B. et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952.
57. Tepmongkol, S., Keelawat, S., Honsawek, S. and Ruangvejvorachai, P. ( 2008) Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 18: 697-704.
58. Viglietto, G., Maglione, D., Rambaldi, M., Cerutti, J., Romano, A., Trapasso, F. et al. (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11: 1569-1579.
59. Wells Jr, S.A., Gosnell, J.E., Gagel, R.F., Moley, J.F., Pfister, D.G., Sosa, J.A. et al. (2007) Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 25: Abstract 6018.
60. Williams, S.D., Birch, R. and Einhorn, L.H. ( 1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70: 405-407.
61. Woyach, J.A., Kloos, R.T., Ringel, M.D., Arbogast, D., Collamore, M., Zwiebel, J.A. et al. (2009) Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94: 164-170.
62. Zarnegar, R., Brunaud, L., Kanauchi, H., Wong, M., Fung, M., Ginzinger, D. et al. (2002) Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132: 984-990.